Wedbush maintains Beam Therapeutics at Outperform, raises price target to $33 from $30

Wedbush reaffirmed its Outperform rating for Beam Therapeutics and increased its price target to $33 from $30, suggesting a 31.2% upside from the Nov 10 close of $25.15. Recent analyst price targets for the company range from $30 to $80.

Original reporting
Published Nov 11, 2026, 2:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 2:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wedbush maintains Beam Therapeutics at Outperform, raises price target to $33 from $30 — source image
Decision brief

The 30-second read

$BEAMBullishLow
01

Why it matters

For traders, the actionable element is the incremental sentiment from the target raise, but the lack of new company-specific information limits conviction.

02

Market read

This is primarily a sentiment/expectations update rather than a new fundamental catalyst.

03

What to watch

The article does not state the thesis behind the target change, nor does it provide any new clinical, regulatory, or financial datapoint that would justify a durable repricing.

Relevance 4/10Novelty 4/10Timing: today’s analyst note update, no scheduled company event cited

Background

The piece is a sell-side update: Wedbush maintained an Outperform rating and increased its Beam Therapeutics price target.

Company-level read

Ticker impact

$BEAMBullishMedium confidence
Context

Wedbush maintained Beam Therapeutics at Outperform and raised its price target to $33 from $30, implying upside versus the Nov 10 close.

Expected impact

Mild upward bias as traders price in improved sell-side expectations, with limited follow-through unless new clinical or financial data emerges.

Evidence & confidence

The article contains only an analyst rating and price-target change, plus implied upside math, with no new trial, regulatory, or company-specific operational disclosure.

Market effects

Small read-through for biotech sentiment, but no sector-wide policy or data catalyst is provided.

No specific regional market linkage beyond general biotech risk appetite.

Limited global relevance since the update is a single-name analyst target change.

Counterpoint

Price-target increases can lag or reverse if subsequent trial readouts or financing needs disappoint, so the move may fade without new fundamentals.

Key entities

  • Beam Therapeutics

    Subject of the analyst rating and price-target change described in the article.

  • Wedbush

    Brokerage issuing the Outperform maintenance and raised price target.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.